# HTT EXON1 Research Report **Protein:** HTT EXON1 **Variant:** Q23_exon1 **UniProt ID:** P42858 **Disease Association:** Huntington's disease **Report Generated:** 2026-07-29 20:31 UTC **AlphaFold Confidence (pLDDT):** 79.7% **Structure Folded:** 2026-07-26 --- ## Structure Summary The Q23_exon1 variant represents a normal, non-disease form of Huntington's disease protein (HTT) with 23 glutamine repeats in its first exon—below the 36-repeat threshold that causes disease symptoms. This AlphaFold2 structure prediction (average confidence 79.7) provides insight into the healthy protein's structure, which serves as an important reference point for understanding how longer, disease-causing repeat expansions alter the protein's behavior and lead to the toxic aggregates that kill brain cells in Huntington's disease. Comparing normal and expanded forms helps researchers identify structural changes that could be targeted for therapy. --- Huntington's disease (HD) is caused by an expansion of CAG trinucleotide repeats in exon 1 of the HTT gene, which encodes a polyglutamine (polyQ) tract in the huntingtin protein. While pathological expansions exceed 36 repeats [2][5], the Q23_exon1 variant analyzed here represents a normal allele with 23 glutamine repeats—well within the healthy range. This structure prediction provides a reference for understanding how the normal HTT exon 1 region is organized before pathological expansion occurs. The AlphaFold2 structure prediction achieved an average confidence score (pLDDT) of 79.7, indicating moderately high confidence overall. However, it is important to note that intrinsically disordered regions, which are common in polyglutamine-containing proteins, typically receive lower confidence scores even when the prediction accurately reflects their flexible nature. The exon 1 region of huntingtin includes the polyQ tract followed by a proline-rich domain, and both regions are known to influence protein aggregation behavior in disease states [5][6]. In Huntington's disease, CAG repeat expansion leads to production of mutant huntingtin (mHTT) that misfolds and forms toxic aggregates, ultimately causing selective degeneration of striatal medium spiny neurons [1][8]. The length of the CAG expansion is the primary determinant of age of disease onset, with longer repeats leading to earlier symptom appearance [2][3]. Recent research has revealed that the loss of interrupting CCG codons within the repeat tract (CAG-CCG LOI variants) can lead to underestimation of true repeat length and affect disease progression predictions [2]. Understanding the structural differences between normal-length polyQ tracts (like Q23) and pathological expansions is critical for developing therapies that might prevent or reverse protein misfolding. The normal huntingtin protein plays important roles in neuronal function and survival. Research shows that HTT regulates striatal neuron excitability in the adult brain, and loss of wild-type HTT function contributes to disease pathology [1]. This suggests that Huntington's disease involves both toxic gain-of-function from the mutant protein aggregates and loss of normal protein function. The Q23_exon1 structure represents the functional form of this essential protein domain, providing a baseline for understanding how repeat expansion disrupts normal cellular activities. Studies have demonstrated that mutant huntingtin aggregates can form insoluble inclusion bodies, though whether these structures are protective or detrimental remains debated [6]. The formation of these aggregates depends heavily on polyQ length, with longer tracts showing increased propensity for misfolding and aggregation [5]. Metabolic and transcriptional changes appear early in disease progression, even before overt neurodegeneration [4], suggesting that structural alterations in the expanded polyQ region trigger cascading cellular dysfunction. Comparing the Q23 normal variant structure to predictions of pathological expansions could help identify specific structural features that promote aggregation and neurotoxicity, potentially revealing new therapeutic targets for this currently incurable disease [7]. ## Works Cited [1] Barron et al. (2026). Striatal Neuron Excitability Is Regulated by Huntingtin in the Adult Brain. eNeuro. [PubMed](https://pubmed.ncbi.nlm.nih.gov/42209021/) [2] Findlay et al. (2026). Clinical implications of loss of interruption variants for diagnosis, genetic counselling, and clinical trials in Huntington's disease. Journal of Huntington's disease. [PubMed](https://pubmed.ncbi.nlm.nih.gov/42202221/) [3] Wheildon et al. (2026). DNA methylation profiling in Huntington's disease reveals disease associated changes in the striatum. Clinical epigenetics. [PubMed](https://pubmed.ncbi.nlm.nih.gov/42185880/) [4] Rysankova et al. (2026). Induced pluripotent stem cells from a transgenic minipig model of Huntington's disease reveal early metabolic changes. Disease models & mechanisms. [PubMed](https://pubmed.ncbi.nlm.nih.gov/42109206/) [5] Szulc et al. (2026). Extensive transcriptomic changes in cellular and animal models of Huntington's disease depending on the length of CAG repeats in the exon 1 of the HTT gene. Biochemical and biophysical research communications. [PubMed](https://pubmed.ncbi.nlm.nih.gov/41926793/) [6] Oweis et al. (2026). ATF3-dependent formation of inclusion bodies in polyQ-expressing human iPSC-derived neurons confers cellular protection. Cell death and differentiation. [PubMed](https://pubmed.ncbi.nlm.nih.gov/41922802/) [7] Gaffke et al. (2026). Genistein (5,7-dihydroxy-3-(4-hydroxyphenyl)-4H-1-benzopyran-4-one) Is Effective in Reducing Symptoms of Huntington's Disease in Females of the R6/1 Mouse Model. Frontiers in bioscience (Landmark edition). [PubMed](https://pubmed.ncbi.nlm.nih.gov/42411471/) [8] Lee et al. (2026). CDKN1A protects medium spiny neurons from Huntington's disease pathology. Neurobiology of disease. [PubMed](https://pubmed.ncbi.nlm.nih.gov/42409247/) ## Similar Research **Unraveling the genetic architecture of non-Huntington chorea: a biobank-scale study of rare variants and repeat expansions.** Akcimen et al. (2026) *Relevant to Huntington's disease research* [Read on PubMed](https://pubmed.ncbi.nlm.nih.gov/41957010/) **Aberrant expression of the MID1 protein in neurons of Huntington's disease brain.** Geraci et al. (2026) *Relevant to Huntington's disease research* [Read on PubMed](https://pubmed.ncbi.nlm.nih.gov/41884622/) **Mitochondria "Shackled" by Mutant Huntingtin: Analysis of Morphological Alterations and Disruptions of Intracellular Transport.** Pasko et al. (2026) *Relevant to Huntington's disease research* [Read on PubMed](https://pubmed.ncbi.nlm.nih.gov/41843843/) **Huntington's disease LIG1 modifier variant increases ligase fidelity and suppresses somatic CAG repeat expansion.** Lee et al. (2026) *Relevant to Huntington's disease research* [Read on PubMed](https://pubmed.ncbi.nlm.nih.gov/41770933/) **Contribution of neuroepigenetics to HD - developmental and aging-related signatures.** Scuto et al. (2026) *Relevant to Huntington's disease research* [Read on PubMed](https://pubmed.ncbi.nlm.nih.gov/41755664/) --- ## AI Research Brief # Research Brief: HTT Exon 1 Q23 Variant ## Pathogenic Mechanisms The HTT exon 1 Q23 variant represents a polyglutamine expansion in the huntingtin protein associated with Huntington's disease pathology. Literature findings establish that pathogenicity involves complex molecular mechanisms centered on the N17 domain, particularly leucine 7, which mediates mitochondrial dysfunction. The polyglutamine expansion creates both gain-of-function toxicity through protein aggregation and loss-of-function effects through altered chromatin architecture. The variant's molecular functions include critical cytoskeletal interactions through beta-tubulin binding and motor protein complex formation via dynactin and dynein intermediate chain binding. These interactions are essential for establishment of mitotic spindle orientation and central nervous system development, suggesting that disruption of these processes contributes to neurodegeneration. The pathology involves tissue-specific molecular signatures, with protein aggregation driving progressive dysfunction in affected neural tissues through mechanisms that extend beyond simple protein misfolding to include disruption of fundamental cellular processes including apoptotic signaling. ## Clinical Significance The Q23 polyglutamine expansion in HTT exon 1 represents an intermediate-length repeat that falls within the pathogenic range for Huntington's disease, though specific population frequency data and formal pathogenicity classifications were not available in the current dataset. The variant's clinical impact stems from interference with huntingtin's normal cellular functions, including its roles in microtubule-based transport, ubiquitination processes (interactions with UBE2K, RNF20), and membrane trafficking (ARFGAP3 interaction). The disruption of these protein-protein interactions, particularly with ZDHHC17 and UBAC1, likely contributes to the neurodegenerative phenotype through cumulative cellular dysfunction affecting multiple pathways essential for neuronal health and survival. ## Therapeutic Landscape A promising aggregation hotspot has been identified at residues 1497-1501 with a high aggregation propensity score of 0.83, providing a rational target for therapeutic intervention. The candidate peptide CP-HTT-001 has been computationally designed to specifically target this high-scoring aggregation region, offering potential to disrupt pathological protein-protein interactions and reduce aggregate formation. The therapeutic strategy encompasses multiple approaches including targeting N17 domain-mediated mitochondrial dysfunction and modulating chromatin architecture changes. The cross-variant synthesis suggests a multi-modal therapeutic landscape, though specific peptide inhibitors with published PMID references were not detailed in the available data. ## Research Directions Critical knowledge gaps remain in understanding tissue-specific vulnerability patterns and the relative contributions of gain- versus loss-of-function mechanisms in different neural populations. Priority research directions should include: (1) validation of CP-HTT-001 peptide efficacy in cellular and animal models; (2) detailed characterization of how the Q23 expansion specifically affects interactions with ZDHHC17, UBAC1, and other critical binding partners; (3) investigation of whether targeting the 1497-1501 aggregation hotspot can preserve normal huntingtin functions while reducing toxicity; and (4) elucidation of the molecular basis for tissue-specific pathology to enable targeted therapeutic strategies for vulnerable brain regions. --- ## Agent Findings ### Literature (1) - **2026-07-26:** These papers are highly relevant to understanding HTT exon 1 Q23 pathology in Huntington's disease, particularly focusing on the N17 domain structure and its role in protein aggregation, mitochondrial targeting, and toxicity. The findings identify specific therapeutic targets within exon 1 (especially L7 residue) and reveal distinct gain-of-function versus loss-of-function mechanisms associated with the CAG repeat expansion that may inform targeted treatment strategies. ### Synthesis (1) - **2026-07-27:** Synthesis of 3 findings (literature, peptides, supplements): The HTT exon 1 Q23 variant in Huntington's disease shows a promising therapeutic landscape with mult... --- *Generated by [Clarity Protocol](https://clarityprotocol.io)* **Data Sources:** - Structure predictions: AlphaFold via ColabFold - Clinical variant data: ClinVar, gnomAD - Disease associations: Open Targets Platform - Research findings: AI agents (PubMed, clinical databases)